Johnson and Johnson: XARELTO Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
September 20, 2019
September 20, 2019
TITUSVILLE, New Jersey, Sept. 20 -- Johnson and Johnson issued the following news release:
* * *
- New real-world study of patients with venous thromboembolism and morbid obesity shows safety and effectiveness of XARELTO were similar to warfarin, with significantly less healthcare resource utilization and total medical costs
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today important new real-world evidence con . . .
* * *
- New real-world study of patients with venous thromboembolism and morbid obesity shows safety and effectiveness of XARELTO were similar to warfarin, with significantly less healthcare resource utilization and total medical costs
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today important new real-world evidence con . . .